1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Scott, A. Pantoja-Uceda, D. Koshiba, S. Inoue, M. Kigawa, T. Terada, T. Shirouzu, M. Tanaka, A. Sugano, S. Yokoyama, S. Guntert, P. RIKEN Structural Genomics/Proteomics Initiative (RSGI) http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking NE J.Biomol.NMR JBNME9 0800 0925-2738 31 357 361 10.1007/s10858-005-0946-6 15929003 Solution structure of the Src homology 2 domain from the human feline sarcoma oncogene Fes 2005 To be Published 0353 NMR assignment of the SH2 domain from the human feline sarcoma oncogene FES 10.2210/pdb1wqu/pdb pdb_00001wqu 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 12506.106 Proto-oncogene tyrosine-protein kinase FES/FPS 2.7.1.112 SH2 domain 1 man polymer C-FES no no GSSGSSGEVQKPLHEQLWYHGAIPRAEVAELLVHSGDFLVRESQGKQEYVLSVLWDGLPRHFIIQSLDNLYRLEGEGFPS IPLLIDHLLSTQQPLTKKSGVVLHRAVPSGPSSG GSSGSSGEVQKPLHEQLWYHGAIPRAEVAELLVHSGDFLVRESQGKQEYVLSVLWDGLPRHFIIQSLDNLYRLEGEGFPS IPLLIDHLLSTQQPLTKKSGVVLHRAVPSGPSSG A hss001002011.2 polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n human Homo sample cell-free protein synthesis 9606 Homo sapiens plasmid p040524-01 RIKEN Structural Genomics/Proteomics Initiative RSGI database_2 pdbx_nmr_spectrometer pdbx_struct_assembly pdbx_struct_oper_list struct_ref_seq_dif repository Initial release Version format compliance Version format compliance Data collection Database references Derived calculations 1 0 2005-06-14 1 1 2008-04-30 1 2 2011-07-13 1 3 2022-03-02 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_nmr_spectrometer.model _struct_ref_seq_dif.details Y PDBJ Y PDBJ 2004-10-02 REL structures with the least restraint violations 100 20 3D_13C-separated_NOESY 3D_15N-separated_NOESY 7.0 AMBIENT 298 K automated NOESY assignment, torsion angle dynamics, energy minimization 1 closest to the average 1.2mM uniformly 13C and 15N labeled protein; 20mM Tris-HCl buffer; 100mM NaCl; 1mM dithiothreitol; 0.02% NaN3 90% H2O/10% D2O Delaglio, F. processing NMRPipe 2.1 Johnson, B. data analysis NMRView 5.0.4 Guntert, P. structure solution CYANA 2.0.32 Koradi, R., Billeter, M., Guntert, P. refinement OPALp 1.3 600 Bruker DRX 800 Bruker AVANCE GLY 1 n 1 GLY 1 A SER 2 n 2 SER 2 A SER 3 n 3 SER 3 A GLY 4 n 4 GLY 4 A SER 5 n 5 SER 5 A SER 6 n 6 SER 6 A GLY 7 n 7 GLY 7 A GLU 8 n 8 GLU 8 A VAL 9 n 9 VAL 9 A GLN 10 n 10 GLN 10 A LYS 11 n 11 LYS 11 A PRO 12 n 12 PRO 12 A LEU 13 n 13 LEU 13 A HIS 14 n 14 HIS 14 A GLU 15 n 15 GLU 15 A GLN 16 n 16 GLN 16 A LEU 17 n 17 LEU 17 A TRP 18 n 18 TRP 18 A TYR 19 n 19 TYR 19 A HIS 20 n 20 HIS 20 A GLY 21 n 21 GLY 21 A ALA 22 n 22 ALA 22 A ILE 23 n 23 ILE 23 A PRO 24 n 24 PRO 24 A ARG 25 n 25 ARG 25 A ALA 26 n 26 ALA 26 A GLU 27 n 27 GLU 27 A VAL 28 n 28 VAL 28 A ALA 29 n 29 ALA 29 A GLU 30 n 30 GLU 30 A LEU 31 n 31 LEU 31 A LEU 32 n 32 LEU 32 A VAL 33 n 33 VAL 33 A HIS 34 n 34 HIS 34 A SER 35 n 35 SER 35 A GLY 36 n 36 GLY 36 A ASP 37 n 37 ASP 37 A PHE 38 n 38 PHE 38 A LEU 39 n 39 LEU 39 A VAL 40 n 40 VAL 40 A ARG 41 n 41 ARG 41 A GLU 42 n 42 GLU 42 A SER 43 n 43 SER 43 A GLN 44 n 44 GLN 44 A GLY 45 n 45 GLY 45 A LYS 46 n 46 LYS 46 A GLN 47 n 47 GLN 47 A GLU 48 n 48 GLU 48 A TYR 49 n 49 TYR 49 A VAL 50 n 50 VAL 50 A LEU 51 n 51 LEU 51 A SER 52 n 52 SER 52 A VAL 53 n 53 VAL 53 A LEU 54 n 54 LEU 54 A TRP 55 n 55 TRP 55 A ASP 56 n 56 ASP 56 A GLY 57 n 57 GLY 57 A LEU 58 n 58 LEU 58 A PRO 59 n 59 PRO 59 A ARG 60 n 60 ARG 60 A HIS 61 n 61 HIS 61 A PHE 62 n 62 PHE 62 A ILE 63 n 63 ILE 63 A ILE 64 n 64 ILE 64 A GLN 65 n 65 GLN 65 A SER 66 n 66 SER 66 A LEU 67 n 67 LEU 67 A ASP 68 n 68 ASP 68 A ASN 69 n 69 ASN 69 A LEU 70 n 70 LEU 70 A TYR 71 n 71 TYR 71 A ARG 72 n 72 ARG 72 A LEU 73 n 73 LEU 73 A GLU 74 n 74 GLU 74 A GLY 75 n 75 GLY 75 A GLU 76 n 76 GLU 76 A GLY 77 n 77 GLY 77 A PHE 78 n 78 PHE 78 A PRO 79 n 79 PRO 79 A SER 80 n 80 SER 80 A ILE 81 n 81 ILE 81 A PRO 82 n 82 PRO 82 A LEU 83 n 83 LEU 83 A LEU 84 n 84 LEU 84 A ILE 85 n 85 ILE 85 A ASP 86 n 86 ASP 86 A HIS 87 n 87 HIS 87 A LEU 88 n 88 LEU 88 A LEU 89 n 89 LEU 89 A SER 90 n 90 SER 90 A THR 91 n 91 THR 91 A GLN 92 n 92 GLN 92 A GLN 93 n 93 GLN 93 A PRO 94 n 94 PRO 94 A LEU 95 n 95 LEU 95 A THR 96 n 96 THR 96 A LYS 97 n 97 LYS 97 A LYS 98 n 98 LYS 98 A SER 99 n 99 SER 99 A GLY 100 n 100 GLY 100 A VAL 101 n 101 VAL 101 A VAL 102 n 102 VAL 102 A LEU 103 n 103 LEU 103 A HIS 104 n 104 HIS 104 A ARG 105 n 105 ARG 105 A ALA 106 n 106 ALA 106 A VAL 107 n 107 VAL 107 A PRO 108 n 108 PRO 108 A SER 109 n 109 SER 109 A GLY 110 n 110 GLY 110 A PRO 111 n 111 PRO 111 A SER 112 n 112 SER 112 A SER 113 n 113 SER 113 A GLY 114 n 114 GLY 114 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 A N GLY 21 A N GLY 21 A O GLU 42 A O GLU 42 A N LEU 39 A N LEU 39 A O SER 52 A O SER 52 A N LEU 51 A N LEU 51 A O PHE 62 A O PHE 62 A N GLY 21 A N GLY 21 A O GLU 42 A O GLU 42 A N PHE 38 A N PHE 38 A O ARG 105 A O ARG 105 A N GLN 65 A N GLN 65 A O ARG 72 A O ARG 72 6 A A OE1 HG1 GLU THR 74 96 1.57 2 A TYR 19 0.077 SIDE CHAIN 2 A ARG 72 0.089 SIDE CHAIN 2 A ARG 105 0.086 SIDE CHAIN 3 A ARG 72 0.123 SIDE CHAIN 5 A TYR 19 0.088 SIDE CHAIN 5 A ARG 60 0.088 SIDE CHAIN 7 A ARG 105 0.081 SIDE CHAIN 12 A ARG 41 0.079 SIDE CHAIN 15 A ARG 25 0.091 SIDE CHAIN 15 A ARG 105 0.100 SIDE CHAIN 18 A ARG 41 0.092 SIDE CHAIN 20 A ARG 41 0.094 SIDE CHAIN 4 3.18 0.50 120.30 123.48 A A A NE CZ NH1 ARG ARG ARG 72 72 72 N 1 A ALA 22 -74.92 26.89 1 A ASP 56 56.07 8.02 1 A LEU 67 -153.89 -61.05 1 A ASP 68 -78.23 30.65 1 A LEU 73 -142.71 -33.13 1 A GLU 74 -156.93 -31.20 1 A SER 99 -134.53 -39.44 2 A VAL 33 -131.12 -31.59 2 A GLN 47 -75.97 37.41 2 A ILE 63 -67.98 97.02 2 A ILE 64 -56.38 108.68 2 A GLU 74 -155.57 -56.48 3 A HIS 14 -65.60 0.53 3 A ALA 22 -76.75 25.30 3 A GLN 47 57.85 12.70 3 A ASP 56 49.24 18.72 3 A ASN 69 70.73 -5.03 3 A LEU 73 -131.27 -36.28 3 A GLU 74 -159.69 -20.35 4 A LEU 73 -142.80 -49.39 5 A ALA 22 -71.82 43.03 5 A TRP 55 -152.56 -85.89 5 A ASP 56 -79.24 23.85 5 A PRO 59 -68.62 92.66 5 A LEU 67 -130.09 -81.06 5 A ASP 68 -75.73 37.69 6 A SER 3 -108.46 -151.60 6 A ALA 22 38.89 18.91 6 A ASP 56 55.70 2.00 6 A ASP 68 49.95 22.96 6 A LEU 73 -125.26 -78.70 6 A THR 96 -177.53 141.89 7 A VAL 33 -136.21 -35.88 7 A GLN 44 -41.77 107.51 7 A TRP 55 -149.20 -63.35 7 A ASP 56 -107.24 42.53 7 A LEU 67 -150.28 -5.09 7 A LEU 73 -150.90 -32.59 7 A GLU 74 -113.20 -71.81 7 A SER 113 -55.04 102.72 8 A SER 3 -75.45 -169.58 8 A ALA 22 -66.91 26.68 8 A ASP 68 56.63 18.00 8 A ASN 69 91.90 2.99 8 A LEU 73 -127.20 -83.90 8 A PRO 111 -68.26 38.43 9 A SER 2 -61.04 4.27 9 A ALA 22 46.66 11.40 9 A LYS 46 -65.45 24.23 9 A TRP 55 -145.30 -97.88 10 A SER 3 -104.67 -90.59 10 A SER 5 -51.28 104.42 10 A GLN 47 -73.37 36.26 10 A TRP 55 -150.42 -36.36 10 A LEU 67 -127.77 -89.76 10 A ASN 69 64.97 -3.92 10 A GLU 74 60.01 -6.96 11 A ALA 22 35.49 17.89 11 A VAL 33 -142.70 -29.45 11 A GLN 47 -96.75 40.55 11 A LEU 67 -130.48 -61.82 11 A ASP 68 -82.77 43.75 11 A ASN 69 61.48 -1.03 11 A LEU 73 -130.03 -53.45 11 A GLU 74 -141.12 -39.71 11 A LYS 98 -66.57 4.80 12 A SER 5 -148.24 20.79 12 A HIS 14 -67.64 0.02 12 A ALA 22 -69.11 29.64 12 A ASP 56 55.73 11.29 12 A LEU 73 -144.58 -33.14 12 A GLU 74 -150.80 -61.06 12 A LYS 98 -44.65 -76.17 12 A PRO 111 -80.49 44.51 13 A SER 2 -116.72 -83.65 13 A ALA 22 -69.99 27.70 13 A VAL 33 -131.83 -30.25 13 A GLN 44 -70.23 26.40 13 A LEU 73 -131.32 -44.33 13 A GLU 74 -139.32 -50.80 13 A LYS 98 -54.68 -74.50 13 A SER 112 -55.75 171.96 14 A ALA 22 -67.02 18.58 14 A GLN 44 -66.34 22.49 14 A TRP 55 -141.73 -51.45 14 A LEU 67 -136.89 -68.59 14 A ASP 68 -84.84 34.47 14 A GLU 74 -142.95 -14.95 15 A GLN 44 -20.60 101.88 15 A TRP 55 -142.10 -60.61 15 A LEU 67 -109.64 -76.25 15 A ASP 68 -93.81 31.61 15 A ASN 69 79.13 -8.86 15 A PRO 111 -69.08 15.74 16 A SER 3 -142.88 -156.72 16 A SER 5 -68.85 68.27 16 A ILE 23 -38.46 134.79 16 A GLN 44 -3.77 -90.75 16 A GLN 47 44.20 28.13 16 A LEU 67 -160.66 -61.12 16 A ASP 68 -97.60 56.18 16 A ASN 69 59.23 -0.91 16 A GLU 74 58.12 18.73 17 A SER 3 39.97 54.81 17 A SER 5 176.01 -176.07 17 A ALA 22 42.93 20.10 17 A GLU 48 -162.08 114.59 17 A ASP 56 56.65 1.83 17 A PRO 59 -68.84 99.87 17 A LEU 73 -134.00 -30.47 17 A GLU 74 -156.78 -67.36 17 A ARG 105 -172.55 146.26 18 A SER 6 -72.52 25.98 18 A ALA 22 -78.89 49.08 18 A VAL 33 -138.57 -30.76 18 A GLN 47 -73.83 38.15 18 A LEU 67 -147.64 -77.61 18 A ASP 68 -73.05 29.12 18 A ARG 72 155.63 -154.66 18 A LEU 73 -123.61 -79.51 19 A SER 5 -57.48 105.45 19 A SER 43 -68.63 -170.09 19 A PRO 59 -68.35 94.45 19 A LEU 67 -131.48 -78.70 19 A ASP 68 -81.43 35.68 19 A LEU 73 -121.56 -66.96 20 A ALA 22 -75.79 41.14 20 A GLN 44 -47.78 106.08 20 A GLN 47 -119.51 68.98 20 A LEU 67 -132.61 -57.66 20 A LEU 73 -134.36 -39.18 20 A GLU 74 -136.13 -53.80 Solution structure of the human FES SH2 domain 1 N N A GLY 7 A GLY 7 HELX_P A LYS 11 A LYS 11 5 1 5 A PRO 12 A PRO 12 HELX_P A GLN 16 A GLN 16 5 2 5 A PRO 24 A PRO 24 HELX_P A GLU 30 A GLU 30 1 3 7 A SER 80 A SER 80 HELX_P A GLN 92 A GLN 92 1 4 13 TRANSFERASE SH2 domain, FES, feline sarcoma oncogene, structural genomics, RIKEN Structural Genomics/Proteomics Initiative, RSGI, Transferase FES_HUMAN UNP 1 450 P07332 EVQKPLHEQLWYHGAIPRAEVAELLVHSGDFLVRESQGKQEYVLSVLWDGLPRHFIIQSLDNLYRLEGEGFPSIPLLIDH LLSTQQPLTKKSGVVLHRAVP 450 550 1WQU 8 108 P07332 A 1 8 108 1 cloning artifact GLY 1 1WQU A P07332 UNP 1 1 cloning artifact SER 2 1WQU A P07332 UNP 2 1 cloning artifact SER 3 1WQU A P07332 UNP 3 1 cloning artifact GLY 4 1WQU A P07332 UNP 4 1 cloning artifact SER 5 1WQU A P07332 UNP 5 1 cloning artifact SER 6 1WQU A P07332 UNP 6 1 cloning artifact GLY 7 1WQU A P07332 UNP 7 1 cloning artifact SER 109 1WQU A P07332 UNP 109 1 cloning artifact GLY 110 1WQU A P07332 UNP 110 1 cloning artifact PRO 111 1WQU A P07332 UNP 111 1 cloning artifact SER 112 1WQU A P07332 UNP 112 1 cloning artifact SER 113 1WQU A P07332 UNP 113 1 cloning artifact GLY 114 1WQU A P07332 UNP 114 4 3 2 parallel anti-parallel anti-parallel parallel parallel anti-parallel A TYR 19 A TYR 19 A GLY 21 A GLY 21 A ASP 37 A ASP 37 A GLU 42 A GLU 42 A TYR 49 A TYR 49 A TRP 55 A TRP 55 A LEU 58 A LEU 58 A ILE 63 A ILE 63 A TYR 19 A TYR 19 A GLY 21 A GLY 21 A ASP 37 A ASP 37 A GLU 42 A GLU 42 A ARG 105 A ARG 105 A ALA 106 A ALA 106 A GLN 65 A GLN 65 A SER 66 A SER 66 A TYR 71 A TYR 71 A ARG 72 A ARG 72 1 P 1